Xiaoqi Song

Title: Xiaoqi Song: Innovator in Monoclonal Antibody Development

Introduction

Xiaoqi Song is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of biotechnology. He holds a total of 4 patents, focusing primarily on monoclonal antibodies that have potential therapeutic applications.

Latest Patents

One of his latest patents is a monoclonal antibody specifically binding to human and monkey CD38 antigens. This invention includes antigen complementarity-determining regions CDR1, CDR2, and CDR3 of both the antibody light chain and heavy chain variable regions. The monoclonal antibody can be utilized in pharmaceutical compositions for treating tumors with positive CD38 expression, such as human myeloma and lymphoma. Another notable patent involves a monoclonal antibody that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1). This invention also details the preparation process of a human-mouse chimeric antibody and its potential use in treating choroidal neovascularization and other angiogenesis-related diseases.

Career Highlights

Xiaoqi Song has worked with several companies in the biotechnology sector, including Acroimmune Biopharma Co., Ltd. and Suzhou Stainwei Biotech Inc. His work has significantly advanced the development of therapeutic antibodies, contributing to innovative solutions in medical treatments.

Collaborations

Xiaoqi has collaborated with notable professionals in his field, including Hongqun Hu and Zui Chen, enhancing the research and development of his inventions.

Conclusion

Xiaoqi Song's innovative work in monoclonal antibodies showcases his commitment to advancing medical science. His patents reflect a deep understanding of biotechnology and its applications in treating serious health conditions.